SHANGHAI, March 23, 2016 /PRNewswire/ -- Based on the data analysis from CFDA that there are around 5,000 pharmaceutical manufacturers in China in total, and 90% of them manufacture generics. There will be big changes and great adjustment around the year of 2018 due to the changeable policy and market environment.
Hosted by UBM, The 6th NEXTGEN CHINA 2016 will gather all resources of CPhI global and use the past five conferences to explore the above topics and showcase the evolving generics landscape and solutions.
More than 50 guests have registered for the conference, such as Huahai Pharmaceutical Co., Ltd., Luye Pharma Group, NOVARTIS, Merro, Zhijun Pharmaceutical, WANHUA, BeiLu Pharmaceutical and Pfizer. Catch theEarly Bird Deadline before March 25with theonline registration.
Conference Time: April 12-13, 2016
Conference Location: Ballroom in 3F, New World Shanghai Hotel
Hot Speakers and Topics:
- Clarifying and solutions: generics consistency evaluation on quality and efficacy
Professor Bo Wang, Researcher, The Research Center of National Drug Policy & Ecosystem - Implementation and forecast: opportunities for generics manufacturers
Yazhou Sun, Guest Professor, CFDA Institute of Executive Development - Drug Marketing Authorization Holder (MAH), feasibility analysis in China
Professor Yue Yang, Vice Director, College of Business Administration of Shenyang Pharmaceutical University - Monitor of all life cycle in generics quality consistency evaluation
Yueping Sun, WHO Consultant, with 12 years experiences in pharmacology research & 25 years experience with pharmaceutical companies and medical consultation - Strategic cooperation and M&A-how to seek for new chances for generics manufacturers
John Wang, Partner, Pharma Investor, GTJA Investment Group - Promoting the internationalization of China-made Generics by synergizing both internal and external capabilities
Shizhong Luo, General Manager, Beijing Yabao International Trade Co., Ltd - Intellectual property strategy in generics development process
Yunli Xue, Vice President of Pharma IP, Luye Pharma - How to perform meaningful forced degradation studies and the strategies for developing stability-indicating analytical methods
Min Li, PhD, VP of Analytical Operation, Huahai Pharmaceutical Co., Ltd - Liquid chromatography method and impurity profile research method of generics
Baiming Xiao, PhD, Executive Technology Director, Research Institute of Simcere - CMC strategy in impurity control for irinotecan HCI trihydrate salt
Jason Liou, PhD, Senior Director of CMC, Hansyn Pharma - Governing principles of BE testing
Yuhu Zhang, Chief Pharmacist & Senior Reviewer (Retired), Center for Drug Evaluation of CFDA - Guiding significance of in vitro dissolution testing on BE testing
Xiaoming Wu, Deputy General Manager, Pioneer Pharma - Challenges and replies of standardization biological analysis in BE
Xiaohang Shen, PhD, Biological Analysis Expert & CFDA Consultant
Who Will Attend:
- Decision Makers, R&D, Regulatory Affairs, Marketing, BD, QA/QC and Manufactures
- Generics/Biosimilar Manufacturers, Government/Regulatory/Association/Researchers, Innovators Pharma Manufacturers, API, Ingredient & Material, Equipment/Service/IT/PAT Suppliers, CRO/CMO
Download the complete agenda
Download the previous post-conference report
Online Registration
Ms. Julia Zhu
+86-21-6157-3922
julia.zhu@ubm.com
Photo - http://photos.prnewswire.com/prnh/20160323/347219
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-6th-nextgen-conference-china-to-open-soon-300240918.html
SOURCE The 6th NextGen Conference
